NURS5433 Family II (FNP 2) Final Exam 2026/2027 | 450 Verified Q&A | UTA | Graded A+ | Pass Guaranteed - A+ Graded

Pass your NURS5433 Family II (FNP 2) Final Exam at the University of Texas at Arlington with this comprehensive review featuring 450 verified questions and answers – 100% guaranteed pass, graded A+, and fully updated for the latest 2026/2027 curriculum. This A+ Graded resource for the NURS5433 Final Exam – Family II (FNP 2) Review (Latest 2026/2027 Update | UTA) contains 450 verified questions and answers (100% correct) covering every essential topic required for success on the UTA Family Nurse Practitioner final examination. Featuring in-depth coverage of common acute and chronic conditions across the lifespan, evidence-based screening guidelines, pharmacotherapy, and clinical reasoning for differential diagnosis and treatment planning in primary care, it provides the advanced clinical knowledge, critical thinking skills, and test-taking confidence needed to mirror the official UTA FNP 2 final exam format and rigor. Comprehensive Content Coverage Includes: Cardiovascular Conditions: Hypertension management per JNC and ACC/AHA guidelines (staging, lifestyle modifications, first-line pharmacotherapy – thiazides, ACE inhibitors, ARBs, CCBs, beta-blockers; resistant hypertension, hypertensive urgency vs. emergency), heart failure (HFrEF and HFpEF – diagnosis, pharmacologic management with diuretics, beta-blockers, ACE inhibitors/ARBs, ARNIs, SGLT2 inhibitors; monitoring, referral criteria), coronary artery disease (stable angina, acute coronary syndromes, risk stratification, secondary prevention – aspirin, statins, beta-blockers), dyslipidemia (LDL cholesterol targets, statin intensity, non-statin agents – ezetimibe, PCSK9 inhibitors), atrial fibrillation (rate vs. rhythm control, anticoagulation with CHA₂DS₂-VASc and HAS-BLED scores), peripheral arterial disease (screening, claudication management, antiplatelet therapy). Endocrine Disorders: Diabetes mellitus type 2 (diagnostic criteria, initial and add-on pharmacotherapy – metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, thiazolidinediones, insulin initiation and titration; monitoring with HbA1c, continuous glucose monitoring; microvascular and macrovascular complications, sick day management), type 1 diabetes (insulin regimens, hypoglycemia prevention, diabetic ketoacidosis recognition), metabolic syndrome (diagnosis, lifestyle intervention, cardiovascular risk reduction), thyroid disorders (hypothyroidism – levothyroxine dosing, monitoring TSH; hyperthyroidism – Graves' disease, subclinical hyperthyroidism, antithyroid medications, radioactive iodine, surgery; thyroid nodules – evaluation with ultrasound and biopsy), osteoporosis (screening with DEXA, pharmacotherapy – bisphosphonates, denosumab, raloxifene, teriparatide; calcium and vitamin D supplementation, fall prevention). Respiratory Conditions: Asthma (classification, stepwise pharmacotherapy – SABA, ICS, LABA, LTRA, biologics; action plan, inhaler technique), COPD (diagnosis with spirometry, GOLD classification, pharmacotherapy – SAMA, SABA, LAMA, LABA, ICS, roflumilast; oxygen therapy, pulmonary rehabilitation), community-acquired pneumonia (PORT score for severity, outpatient vs. inpatient antibiotics, follow-up), acute bronchitis (appropriate antibiotic stewardship), sinusitis (acute vs. chronic, antibiotic indications), allergic rhinitis (antihistamines, intranasal corticosteroids, immunotherapy). Gastrointestinal Conditions: GERD (lifestyle modifications, PPI therapy, H. pylori testing and treatment for PUD, alarm symptoms for referral), irritable bowel syndrome (IBS-D vs. IBS-C – dietary interventions, fiber, antispasmodics, rifaximin, lubiprostone, linaclotide), inflammatory bowel disease (Crohn's vs. ulcerative colitis – differentiation, initial treatment, monitoring), hepatitis B and C (screening, vaccination, antiviral treatment indications), cirrhosis (complications – ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis; screening for hepatocellular carcinoma), cholelithiasis (symptomatic vs. asymptomatic, surgical referral), pancreatitis (acute vs. chronic, etiology, supportive care). Genitourinary Conditions: Urinary tract infections (uncomplicated cystitis vs. pyelonephritis vs. complicated UTI – antibiotic choice by local resistance patterns, duration of therapy, prophylaxis), benign prostatic hyperplasia (symptom assessment with AUA score, pharmacotherapy – alpha-blockers, 5-alpha-reductase inhibitors; surgical referral), erectile dysfunction (evaluation for vascular and hormonal causes, PDE5 inhibitors, testosterone replacement), chronic kidney disease (staging by eGFR and albuminuria, blood pressure control with ACE inhibitors/ARBs, anemia management, mineral bone disorder, referral to nephrology), menstrual disorders (abnormal uterine bleeding – PALM-COEIN classification, hormonal and non-hormonal management), polycystic ovary syndrome (diagnostic criteria, metformin, lifestyle, contraception, fertility management), pelvic pain (differential diagnosis – endometriosis, interstitial cystitis, pelvic inflammatory disease; treatment options). Musculoskeletal Conditions: Osteoarthritis (non-pharmacologic – weight loss, exercise; pharmacologic – acetaminophen, NSAIDs, topical agents; intra-articular injections, surgical referral), rheumatoid arthritis (diagnostic criteria, DMARDs – methotrexate, biologics, JAK inhibitors; monitoring for toxicity), low back pain (red flags – cauda equina syndrome, fracture, infection, malignancy; conservative treatment, imaging indications, epidural steroid injections), gout (acute management – NSAIDs, colchicine, corticosteroids; chronic urate-lowering therapy – allopurinol, febuxostat), fibromyalgia (diagnosis, non-pharmacologic – CBT, exercise; pharmacologic – duloxetine, milnacipran, pregabalin, gabapentin), bursitis/tendinopathy (conservative care, corticosteroid injections). Neurological Conditions: Headache disorders (migraine – acute treatment with triptans, gepants, NSAIDs; prophylaxis with beta-blockers, antidepressants, anticonvulsants, CGRP antagonists; tension-type headache, cluster headache), dizziness (BPPV – Epley maneuver; vestibular neuritis; orthostatic hypotension), peripheral neuropathy (diabetic and idiopathic – management with gabapentin, pregabalin, duloxetine, tricyclic antidepressants), seizures (first seizure evaluation, antiepileptic drug selection, monitoring), multiple sclerosis (relapse management, disease-modifying therapies), Parkinson's disease (carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, supportive care). Dermatological Conditions: Acne vulgaris (topical retinoids, benzoyl peroxide, antibiotics; oral antibiotics, isotretinoin, hormonal therapy), eczema/atopic dermatitis (moisturizers, topical corticosteroids, calcineurin inhibitors, wet wraps), psoriasis (topical corticosteroids, vitamin D analogs, phototherapy, systemic biologics), cellulitis (oral vs. IV antibiotics, MRSA coverage, treatment duration), tinea infections (topical and oral antifungals by site), skin cancer screening (identification of basal cell carcinoma, squamous cell carcinoma, melanoma – ABCDE criteria, biopsy indications). Psychiatric Conditions: Major depressive disorder (screening with PHQ-9, SSRI/SNRI selection and monitoring, treatment duration, referral for therapy), generalized anxiety disorder (GAD-7 screening, first-line SSRIs/SNRIs, buspirone, hydroxyzine, benzodiazepine caution), panic disorder (acute and maintenance treatment), insomnia (CBT-I, sleep hygiene, pharmacologic options – doxepin, ramelteon, trazodone, Z-drugs; melatonin), substance use disorders (alcohol use disorder – screening with AUDIT-C, brief intervention, naltrexone, acamprosate, disulfiram; opioid use disorder – MAT with buprenorphine/naloxone, methadone, naltrexone; harm reduction, naloxone distribution). Infectious Diseases: Influenza (diagnosis, antiviral treatment – oseltamivir, baloxavir; prevention with vaccination), COVID-19 (outpatient management – antivirals nirmatrelvir/ritonavir, remdesivir; vaccination recommendations, long COVID recognition), Lyme disease (prophylaxis after tick bite, treatment of early localized and disseminated disease), mononucleosis (supportive care, activity restriction, splenic rupture precautions), sexually transmitted infections (chlamydia, gonorrhea – treatment per CDC guidelines; syphilis staging and treatment; HIV screening, PrEP and PEP, initial evaluation). Health Maintenance and Screening Guidelines: USPSTF A and B recommendations (blood pressure screening, lipid panel, diabetes screening, depression screening, lung cancer with low-dose CT, breast cancer mammography, cervical cancer Pap/HPV testing, colorectal cancer screening – colonoscopy, FIT, Cologuard; prostate cancer PSA shared decision-making, osteoporosis DEXA screening), immunizations (childhood, adult, pregnant, elderly schedules – COVID-19, influenza, pneumococcal, zoster, HPV, Tdap, MMR, hepatitis B, meningococcal), well-child and well-woman visits, preconception and prenatal care, healthy lifestyle counseling (diet, exercise, smoking cessation using the 5 A's, alcohol moderation, safe sex, injury prevention). Pharmacotherapy Principles: First-line and second-line medications across all major drug classes – mechanisms of action, dosing adjustments for renal/hepatic impairment, therapeutic monitoring parameters (INR, glucose, renal function, liver enzymes), common and serious adverse effects, drug-drug interactions (including CYP450 metabolism), drug-disease interactions, pregnancy/lactation safety categories (FDA and LactMed), medication adherence strategies, polypharmacy considerations in older adults. Clinical Reasoning and Differential Diagnosis: Approach to undifferentiated symptoms, generation of differential diagnosis using probability and pattern recognition, selection of appropriate diagnostic tests (sensitivity, specificity, predictive value, cost-effectiveness), interpretation of laboratory and imaging results, integration of patient preferences and values, shared decision-making, development of evidence-based treatment plans, patient education, follow-up scheduling, and criteria for specialist referral. Each of the 450 questions and answers is expert verified to reflect the latest evidence-based guidelines (USPSTF, JNC, ACC/AHA, ADA, ACR, ACOG, CDC, GOLD, GINA, IDSA) and UTA College of Nursing and Health Innovation curriculum standards. With fully verified Q&A across all 450 questions and our 100% Guaranteed Pass, this is the definitive tool to ace your NURS5433 Final Exam on the first attempt and successfully complete your Family Nurse Practitioner program. Get instant access now and start studying today